Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Vyne Therapeutics Inc
Healthcare
P/NCAV
0.27x
Ticker
VYNE
Exchange
NASDAQ
Country
United States
Close
2.32 $
Mkt Cap
23.8M $
EV
-6.8M $
NCAV Burn Rate
-200.8%
Current Ratio
12.73
Debt/Equity
0.0
EV/REV
-16.01x
EV/EBIT
0.2x
EV/FCF
0.3x
Dilution
55.2% p.A
Total Net Income
-553.5M $
Cheapness
99.0%
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average